Standard BioTools (LAB) Competitors $1.30 +0.02 (+1.16%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.31 +0.01 (+0.46%) As of 08/8/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LAB vs. TXG, TRNS, EYPT, ALNT, AEHR, CTKB, SENS, QTRX, QSI, and FEIMShould you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Senseonics (SENS), Quanterix (QTRX), Quantum-Si (QSI), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry. Standard BioTools vs. Its Competitors 10x Genomics Transcat Eyepoint Pharmaceuticals Allient Aehr Test Systems Cytek Biosciences Senseonics Quanterix Quantum-Si Frequency Electronics 10x Genomics (NASDAQ:TXG) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability. Do analysts prefer TXG or LAB? 10x Genomics currently has a consensus target price of $13.50, indicating a potential upside of 9.85%. Standard BioTools has a consensus target price of $2.50, indicating a potential upside of 91.57%. Given Standard BioTools' stronger consensus rating and higher possible upside, analysts plainly believe Standard BioTools is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.42Standard BioTools 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better valuation and earnings, TXG or LAB? Standard BioTools has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.48-$182.63M-$1.30-9.45Standard BioTools$174.43M2.84-$138.88M-$0.35-3.73 Which has more volatility and risk, TXG or LAB? 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Is TXG or LAB more profitable? 10x Genomics has a net margin of -13.13% compared to Standard BioTools' net margin of -78.24%. 10x Genomics' return on equity of -13.15% beat Standard BioTools' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -13.15% -10.20% Standard BioTools -78.24%-22.44%-16.74% Does the media prefer TXG or LAB? In the previous week, 10x Genomics had 15 more articles in the media than Standard BioTools. MarketBeat recorded 20 mentions for 10x Genomics and 5 mentions for Standard BioTools. 10x Genomics' average media sentiment score of 0.95 beat Standard BioTools' score of 0.63 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Standard BioTools 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in TXG or LAB? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 23.2% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Summary10x Genomics beats Standard BioTools on 9 of the 17 factors compared between the two stocks. Get Standard BioTools News Delivered to You Automatically Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LAB vs. The Competition Export to ExcelMetricStandard BioToolsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$489.97M$2.01B$5.44B$9.61BDividend YieldN/AN/A4.61%4.14%P/E Ratio-3.7336.2929.7524.84Price / Sales2.849.66449.1298.65Price / CashN/A50.4836.4258.36Price / Book1.039.268.185.64Net Income-$138.88M-$63.67M$3.26B$265.68M7 Day Performance0.38%0.35%6.88%4.95%1 Month Performance-4.04%-3.57%1.00%0.83%1 Year Performance-19.44%15.90%28.85%22.18% Standard BioTools Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABStandard BioTools3.4207 of 5 stars$1.31+1.2%$2.50+91.6%-21.9%$489.97M$174.43M-3.73620Positive NewsUpcoming EarningsTXG10x Genomics3.7977 of 5 stars$13.68+4.6%$13.23-3.3%-37.1%$1.61B$610.78M-10.521,240Trending NewsEarnings ReportAnalyst ForecastGap UpTRNSTranscat3.2425 of 5 stars$74.80+0.3%$112.20+50.0%-32.1%$694.69M$278.42M47.951,245Positive NewsEarnings ReportEYPTEyepoint Pharmaceuticals1.6477 of 5 stars$10.06+3.6%$25.67+155.1%+11.7%$668.16M$43.27M-4.17120News CoverageEarnings ReportAnalyst ForecastALNTAllient2.5374 of 5 stars$39.67+4.3%$31.00-21.9%+105.3%$643.64M$516.06M67.242,525News CoverageEarnings ReportDividend AnnouncementAEHRAehr Test Systems1.6842 of 5 stars$19.03+13.0%N/A+30.7%$503.77M$58.97M-146.3790Positive NewsCTKBCytek Biosciences2.5396 of 5 stars$3.84+5.5%$5.60+45.8%-25.6%$461.04M$200.45M-42.66500News CoveragePositive NewsSENSSenseonics2.2161 of 5 stars$0.51+3.9%$1.55+205.2%+22.3%$332.21M$23.68M-3.9190QTRXQuanterix1.8589 of 5 stars$6.04+3.1%$13.50+123.5%-62.9%$292.73M$137.42M-4.65460News CoverageEarnings ReportGap DownQSIQuantum-Si2.3708 of 5 stars$1.44-1.4%$3.48+141.3%+49.9%$267.91M$3.06M-2.12150News CoverageEarnings ReportAnalyst RevisionFEIMFrequency Electronics1.2465 of 5 stars$27.73+4.8%N/A+142.4%$257.30M$69.81M11.23200 Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Eyepoint Pharmaceuticals Alternatives Allient Alternatives Aehr Test Systems Alternatives Cytek Biosciences Alternatives Senseonics Alternatives Quanterix Alternatives Quantum-Si Alternatives Frequency Electronics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LAB) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
